1. Home
  2. WWR vs TLPH Comparison

WWR vs TLPH Comparison

Compare WWR & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

BUY

Current Price

$0.41

Market Cap

68.8M

ML Signal

BUY

Logo Talphera Inc.

TLPH

Talphera Inc.

HOLD

Current Price

$1.10

Market Cap

70.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
TLPH
Founded
1977
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
70.3M
IPO Year
2006
2010

Fundamental Metrics

Financial Performance
Metric
WWR
TLPH
Price
$0.41
$1.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$2.17
★ $3.13
AVG Volume (30 Days)
★ 693.8K
127.3K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,151,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.38
$0.69
52 Week High
$1.74
$11.90

Technical Indicators

Market Signals
Indicator
WWR
TLPH
Relative Strength Index (RSI) 24.86 40.64
Support Level $0.38 $1.03
Resistance Level $0.45 $1.13
Average True Range (ATR) 0.03 0.04
MACD -0.01 -0.00
Stochastic Oscillator 1.47 34.38

Price Performance

Historical Comparison
WWR
TLPH

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: